PH12014501646A1 - Substituted phenylazole derivative - Google Patents
Substituted phenylazole derivativeInfo
- Publication number
- PH12014501646A1 PH12014501646A1 PH12014501646A PH12014501646A PH12014501646A1 PH 12014501646 A1 PH12014501646 A1 PH 12014501646A1 PH 12014501646 A PH12014501646 A PH 12014501646A PH 12014501646 A PH12014501646 A PH 12014501646A PH 12014501646 A1 PH12014501646 A1 PH 12014501646A1
- Authority
- PH
- Philippines
- Prior art keywords
- diabetes
- pharmaceutically acceptable
- acceptable salt
- type
- substituted
- Prior art date
Links
- IRTLROCMFSDSNF-UHFFFAOYSA-N 2-phenyl-1h-pyrrole Chemical class C1=CNC(C=2C=CC=CC=2)=C1 IRTLROCMFSDSNF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012007840 | 2012-01-18 | ||
| PCT/JP2013/050710 WO2013108800A1 (ja) | 2012-01-18 | 2013-01-17 | 置換フェニルアゾール誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014501646A1 true PH12014501646A1 (en) | 2014-10-13 |
Family
ID=48799224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014501646A PH12014501646A1 (en) | 2012-01-18 | 2014-07-17 | Substituted phenylazole derivative |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9233958B2 (https=) |
| EP (2) | EP3009433B1 (https=) |
| JP (2) | JP6104181B2 (https=) |
| KR (1) | KR20140113688A (https=) |
| CN (1) | CN104159892A (https=) |
| AU (1) | AU2013210394A1 (https=) |
| BR (1) | BR112014017656A2 (https=) |
| CA (1) | CA2861847A1 (https=) |
| CO (1) | CO7020920A2 (https=) |
| ES (2) | ES2640667T3 (https=) |
| HK (2) | HK1200824A1 (https=) |
| IL (1) | IL233682A0 (https=) |
| IN (1) | IN2014MN01442A (https=) |
| MX (1) | MX2014008790A (https=) |
| NZ (1) | NZ627303A (https=) |
| PH (1) | PH12014501646A1 (https=) |
| RU (1) | RU2014133738A (https=) |
| SG (1) | SG11201404026SA (https=) |
| TW (1) | TWI551590B (https=) |
| WO (1) | WO2013108800A1 (https=) |
| ZA (1) | ZA201405108B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014133738A (ru) | 2012-01-18 | 2016-03-10 | Дайити Санкио Компани, Лимитед | Замещенное производное фенилазола |
| JP2017119628A (ja) * | 2014-05-09 | 2017-07-06 | 日産化学工業株式会社 | 置換アゾール化合物及び糖尿病治療薬 |
| WO2017104782A1 (ja) * | 2015-12-17 | 2017-06-22 | 第一三共株式会社 | オキサジアゾール化合物の製造方法 |
| EP3766879A1 (en) * | 2019-07-19 | 2021-01-20 | Basf Se | Pesticidal pyrazole derivatives |
| CN111388471B (zh) * | 2020-03-03 | 2021-01-12 | 牡丹江医学院 | 一种治疗胆囊炎的药物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0029974D0 (en) * | 2000-12-08 | 2001-01-24 | Glaxo Group Ltd | Chemical compounds |
| JP4958560B2 (ja) | 2003-12-24 | 2012-06-20 | プロシディオン・リミテッド | Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体 |
| AU2005247473A1 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Substituted triazoles as modulators of PPAR and methods of their preparation |
| WO2007003960A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| EP1910290A2 (en) | 2005-06-30 | 2008-04-16 | Prosidion Limited | Gpcr agonists |
| AU2006299092A1 (en) * | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl-(1,2,4)-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals |
| GB0606913D0 (en) * | 2006-04-06 | 2006-05-17 | Prosidion Ltd | Compounds |
| KR20080109075A (ko) * | 2006-04-06 | 2008-12-16 | 프로시디온 리미티드 | 헤테로사이클릭 ｇｐｃｒ 작용제 |
| AU2008279447A1 (en) * | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| BRPI0818338A2 (pt) | 2007-10-16 | 2015-04-22 | Daiichi Sankyo Co Ltd | Composto de pirimidil indolina |
| EP2241558A1 (en) | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
| WO2010119881A1 (ja) | 2009-04-15 | 2010-10-21 | 第一三共株式会社 | インドリン化合物 |
| NZ597895A (en) * | 2009-08-05 | 2012-11-30 | Daiichi Sankyo Co Ltd | Amide derivative |
| CA2770405C (en) | 2009-08-05 | 2015-03-17 | Daiichi Sankyo Company, Limited | Sulfone derivative |
| SG189320A1 (en) * | 2010-10-14 | 2013-05-31 | Daiichi Sankyo Co Ltd | Acylbenzene derivative |
| BR112014001767A2 (pt) | 2011-07-29 | 2017-02-14 | Daiichi Sankyo Co Ltd | composto, composição farmaccêutica, uso de um composto, e, método para o tratamento de uma doença |
| RU2014133738A (ru) | 2012-01-18 | 2016-03-10 | Дайити Санкио Компани, Лимитед | Замещенное производное фенилазола |
-
2013
- 2013-01-17 RU RU2014133738A patent/RU2014133738A/ru not_active Application Discontinuation
- 2013-01-17 MX MX2014008790A patent/MX2014008790A/es unknown
- 2013-01-17 NZ NZ627303A patent/NZ627303A/en not_active IP Right Cessation
- 2013-01-17 IN IN1442MUN2014 patent/IN2014MN01442A/en unknown
- 2013-01-17 JP JP2013554315A patent/JP6104181B2/ja not_active Expired - Fee Related
- 2013-01-17 EP EP15192148.3A patent/EP3009433B1/en not_active Not-in-force
- 2013-01-17 EP EP13738825.2A patent/EP2805941B1/en not_active Not-in-force
- 2013-01-17 SG SG11201404026SA patent/SG11201404026SA/en unknown
- 2013-01-17 US US14/372,832 patent/US9233958B2/en not_active Expired - Fee Related
- 2013-01-17 CA CA2861847A patent/CA2861847A1/en not_active Abandoned
- 2013-01-17 CN CN201380014867.6A patent/CN104159892A/zh active Pending
- 2013-01-17 AU AU2013210394A patent/AU2013210394A1/en not_active Abandoned
- 2013-01-17 WO PCT/JP2013/050710 patent/WO2013108800A1/ja not_active Ceased
- 2013-01-17 ES ES15192148.3T patent/ES2640667T3/es active Active
- 2013-01-17 KR KR1020147019737A patent/KR20140113688A/ko not_active Withdrawn
- 2013-01-17 HK HK15101292.6A patent/HK1200824A1/en unknown
- 2013-01-17 ES ES13738825.2T patent/ES2602962T3/es active Active
- 2013-01-17 BR BR112014017656A patent/BR112014017656A2/pt not_active IP Right Cessation
- 2013-01-17 TW TW102101765A patent/TWI551590B/zh not_active IP Right Cessation
-
2014
- 2014-07-11 ZA ZA2014/05108A patent/ZA201405108B/en unknown
- 2014-07-17 IL IL233682A patent/IL233682A0/en unknown
- 2014-07-17 PH PH12014501646A patent/PH12014501646A1/en unknown
- 2014-07-31 CO CO14166876A patent/CO7020920A2/es unknown
-
2015
- 2015-02-05 HK HK16108406.3A patent/HK1220448A1/en unknown
- 2015-12-01 US US14/956,116 patent/US20160081993A1/en not_active Abandoned
- 2015-12-01 US US14/956,240 patent/US9725438B2/en not_active Expired - Fee Related
-
2016
- 2016-12-20 JP JP2016247095A patent/JP2017052800A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP201706719B (en) | Pirfenidone treatment for patients with atypical liver function | |
| WO2012117000A8 (en) | 3-amino-pyridines as gpbar1 agonists | |
| MX2010009736A (es) | Compuesto heterociclico. | |
| PH12012502369A1 (en) | Purinone derivative | |
| WO2011159067A3 (en) | Thiazole derivatives as sglt2 inhibitors and pharmaceutical composition comprising same | |
| MA33939B1 (fr) | 5-alcynyl-pyrimidines | |
| GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| MX2011011028A (es) | Agonista del receptor beta de hormona tiroidea novedoso. | |
| AU2012284088A8 (en) | Heterocyclic compounds and uses thereof | |
| WO2012149157A3 (en) | Heterocyclic compounds for the inhibition of pask | |
| MY183312A (en) | Pharmaceutical formulation | |
| MX2013001204A (es) | Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares. | |
| MX2013008484A (es) | Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2. | |
| WO2011147951A8 (en) | Cycloamino derivatives as gpr119 agonists | |
| MX2012007582A (es) | Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida. | |
| TN2012000092A1 (en) | Therapeutic agent for mood disorders | |
| PH12014501646A1 (en) | Substituted phenylazole derivative | |
| PH12014501026A1 (en) | [1, 2, 3]triazolo[4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists | |
| PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| WO2012119046A3 (en) | Heterocyclic compounds for the inhibition of pask | |
| WO2012094462A3 (en) | Heterocyclic compounds for the inhibition of pask | |
| WO2013155528A3 (en) | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels | |
| IN2014DN05972A (https=) | ||
| EA201590051A1 (ru) | Новое соединение, обладающее способностью ингибировать фермент 11бета-hsd1, или его фармацевтически приемлемая соль, способ его получения и фармацевтическая композиция, содержащая такое соединение в качестве активного ингредиента | |
| GB201114389D0 (en) | Novel compounds |